SCHEMBL4496705

SCHEMBL4496705

CC(C)(C)OC(=O)c1cc(N(Cc2cccnc2)c2ccc(OC(F)F)c(OC(F)F)c2)ccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
PDE4B Q07343 2/20 0.37
NR1H4 Q96RI1 1/20 0.37
PDK1 Q15118 6/20 0.37
DHODH Q02127 1/20 0.36
JAK2 O60674 2/20 0.36
JAK1 P23458 2/20 0.36
GRM2 Q14416 3/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2B Q13224 1/20 0.35
RIPK1 Q13546 1/20 0.35
ALDH1A1 P00352 2/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
KDM4E B2RXH2 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4201416 0.88 PDE4B (0.41) MAPTLMNAPOLBKMT2APDE4B
SCHEMBL4190983 0.87 DHODH (0.43) MAPTLMNAPOLBKMT2APDE4B
SCHEMBL4196553 0.86 GRM2 (0.40) MAPTLMNAPOLBKMT2APDE4B
SCHEMBL3214843 0.84 GRM2 (0.41) MAPTLMNAPOLBKMT2APDE4B
SCHEMBL3128977 0.83 ALDH1A1 (0.43) MAPTLMNAPOLBKMT2APDE4B
SCHEMBL3126155 0.83 GRM2 (0.43) MAPTLMNAPOLBKMT2APDE4B
SCHEMBL4199757 0.82 PDE4A (0.51) MAPTPDE4BTP53PDE4APDE4C
SCHEMBL3122799 0.82 PDE4B (0.42) MAPTLMNAPOLBKMT2APDE4B
SCHEMBL3120607 0.82 PDE4B (0.39) MAPTLMNAPOLBKMT2APDE4B
SCHEMBL3125310 0.81 GRM2 (0.40) MAPTLMNAPOLBKMT2APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS SCHUMACHER RICHARD A 2009-02-19 US disclosed
US-7405230-B2 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORPORATION (US) 2008-07-29 US disclosed
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs MEMORY PHARMACEUTICALS CORP. (US) 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048255-A1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS PDE4A, PDE4B, PDE3A MAPT 3913/4885LMNA 3261/4885POLB 1404/4885
US-20050119225-A1 Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs PDE4A, PDE4B, PDE3A MAPT 3913/4885LMNA 3261/4885POLB 1404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.